 The CDC estimates a similar number of cases in the European Union (EU) each year.Ridinilazole was designated as a Qualified Infectious Disease Product (‘QIDP’) and was granted Fast Track status by the U.S. FDA.This status is reserved for drugs designed to treat diseases where there is currently a gap in the treatment, or a complete lack thereof.